Johnson & Johnson (JNJ) – Reuters
-
Johnson & Johnson forecasts as much as 6% sales growth in 2024
-
J&J settles first talc cases to go to trial after failed bankruptcies
-
Medical device makers see limited hit from weight-loss drugs
-
J&J to restructure orthopedic business after medical device sales miss
-
J&J to hold 9.5% stake in Kenvue after share exchange offer
-
US FDA approves Johnson & Johnson's blood cancer therapy
-
J&J talc cancer plaintiffs want 6-month ban on further bankruptcy filings
-
J&J shares on track for biggest daily drop in 3 years on talc setback
-
J&J upbeat on 2023 as devices rebound post-COVID, shares jump
-
J&J sues in latest bid to halt Medicare drug price negotiations
-
US FDA revokes emergency use authorization for J&J's COVID vaccine
-
J&J faces new trial over talc cancer claims, amid settlement push
-
Amgen settles patent lawsuit over biosimilar of J&J's big-selling Stelara
-
J&J's proposed talc settlement would pay $400 million to US state AGs
-
J&J to retain all talc-related liabilities from litigation in US, Canada
-
Cancer victims urge US judge to dismiss J&J talc unit second bankruptcy
-
J&J issues cautious 2023 forecast, shares fall
-
J&J talc unit asks judge to halt cancer lawsuits as it pursues $8.9 billion settlement
-
J&J rises as $9 billion talc lawsuit settlement eases overhang on unit spinoff
-
J&J unit files for second bankruptcy to pursue $8.9 billion talc settlement
-
Exclusive-Johnson & Johnson considers refiling talc-liability bankruptcy after appeals-court defeat
-
Johnson & Johnson unit loses bid to stay in bankruptcy during Supreme Court appeal
-
J&J bows out of RSV vaccine race after scrapping trial
-
J&J to seek U.S. Supreme Court review on unit's bankruptcy
-
Judge indicates intention to dismiss J&J talc unit bankruptcy
-
Alcon to pay Johnson & Johnson $199 million to settle eye-laser cases
-
J&J expects inflation, China COVID hit to carry into 2023
-
U.S. fines J&J $9.75 million over kickbacks to surgeon for overseas surgeries
-
J&J to discontinue HIV vaccine trial
-
J&J sues Amgen over plan to sell drug similar to blockbuster Stelara
-
J&J to buy heart pump maker Abiomed for $16.6 billion ahead of consumer health spinoff
-
J&J looks at job cuts despite weathering inflation impact
-
Former J&J executive emerges as front-runner for Biogen top job - STAT News
-
J&J names consumer health business Kenvue ahead of spin-off
-
J&J's cancer drug sales help weather hit from stronger dollar
-
J&J, AbbVie cancer drug significantly slows progression of rare lymphoma: study
-
J&J appoints consumer health head Thibaut Mongon to CEO of spun-off business
-
J&J pulls COVID vaccine sales forecast due to low demand, supply glut
-
J&J settles West Virginia opioid litigation for $99 million
-
J&J to stop selling personal care products in Russia
-
Judge greenlights J&J strategy to resolve talc lawsuits in bankruptcy court
-
Drug distributors, J&J agree to finalize $26 billion opioid settlement
-
Johnson & Johnson defends talc bankruptcy strategy called 'rotten' by cancer plaintiffs
-
Special Report-Inside J&J’s secret plan to cap litigation payouts to cancer victims
-
J&J expects jump in COVID vaccine sales in 2022, eyes device deals
-
J&J booster 85% effective against Omicron hospitalisation, S.Africa says
-
J&J says its single dose protects against breakthrough COVID-19 for up to 6 months
-
Nevada to join $26 billion opioid settlement with drug distributors, J&J
-
U.S. Supreme Court snubs J&J's bid to avoid Mississippi talc lawsuit
-
J&J sees potential for 14 new multibillion-dollar drugs by 2025
Back to JNJ Stock Lookup
